Company News

FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at the 21st Scientific Meeting of the American Society of Nuclear Cardiology

MONTCLAIR, NJ -- (Marketwired) -- 05/25/16 -- FluoroPharma Medical Inc., (OTCQB: FPMI) today announced the acceptance of the first comparative data from it's Phase II trial of CardioPET in subjects with a high likelihood of coronary artery disease (CAD). The abstract was accepted for oral presentation on September 24th, 2016 in Boca Raton, Florida.

"We are excited that imaging data from this trial was accepted for presentation at such a prestigious forum as ASNC," said the Company's Vice-President of Development, Edward Lyons. "This is an important step in understanding the unique clinical potential for PET-based fatty acid imaging in patients with coronary disease."

CardioPET is a Fluorine-18 labeled modified fatty acid that mimics the heart's primary energy source, and provides insight to coronary blood flow and metabolism. Metabolic disorders are common with the high rates of CAD throughout the developed world. The trial was designed to evaluate the uptake and distribution of CardioPET in comparison to the standard of care for patients with known or suspected CAD, SPECT imaging with Tc-99m agents. Subjects were enrolled based on abnormal SPECT findings indicating ischemia.

ASNC Past President and study author Gary Heller, MD, of Morristown Medical Center in Morristown, New Jersey, performed the analysis of the SPECT and PET images with the clinical investigators, who acquired the image data at four sites in Belgium. After scoring the SPECT and PET images in accordance with ASNC standards, the data were compared to clinically indicated angiography for each subject who received imaging. Dr. Manuel Cerqueira of the Cleveland Clinic, who was instrumental in defining the scoring standard, was also a co-author on the study. Additional observations on image quality and study interpretability were recorded.

The Company's President and CEO, Dr. Thomas Tulip added, "This is the most important step in the drug development process; obtaining results that create scientific debate and facilitate the transition to late-stage clinical studies, enabling a clear development strategy. We believe this new CardioPET data will stimulate strong interest in the Cardiology imaging community. We're looking forward to the presentation, and to proceeding to the critical next stage in clinical development."

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

FluoroPharma's initial focus is the development of breakthrough PET imaging agents and the company is advancing two products in clinical trials for assessment of acute and chronic forms of heart disease. These novel agents have been designed to rapidly target myocardial cells. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia and Mexico. For more information on the company, please visit:

Forward-Looking Statements

Except for historical information contained herein, this release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in FluoroPharma's business. Examples of forward-looking statements include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and FluoroPharma undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.


Source: FluoroPharma Medical, Inc.